Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality among Patients with Hypertension Hospitalized with COVID-19
Peng Zhang,Lihua Zhu,Jingjing Cai,Fang Lei,Juan-Juan Qin,Jing Xie,Ye-Mao Liu,Yan-Ci Zhao,Xuewei Huang,Lijin Lin,Meng Xia,Ming-Ming Chen,Xu Cheng,Xiao Zhang,Deliang Guo,Yuanyuan Peng,Yan-Xiao Ji,Jing Chen,Zhi-Gang She,Yibin Wang,Qingbo Xu,Renfu Tan,Haitao Wang,Jun Lin,Pengcheng Luo,Shouzhi Fu,Hongbin Cai,Ping Ye,Bing Xiao,Weiming Mao,Liming Liu,Youqin Yan,Mingyu Liu,Manhua Chen,Xiao-Jing Zhang,Xinghuan Wang,Rhian M. Touyz,Jiahong Xia,Bing-Hong Zhang,Xiaodong Huang,Yufeng Yuan,Loomba Rohit,Peter P. Liu,Hongliang Li
DOI: https://doi.org/10.1161/circresaha.120.317134
IF: 23.213
2020-01-01
Circulation Research
Abstract:Rationale: Use of ACEIs (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) is a major concern for clinicians treating coronavirus disease 2019 (COVID-19) in patients with hypertension. Objective: To determine the association between in-hospital use of ACEI/ARB and all-cause mortality in patients with hypertension and hospitalized due to COVID-19. Methods and Results: This retrospective, multi-center study included 1128 adult patients with hypertension diagnosed with COVID-19, including 188 taking ACEI/ARB (ACEI/ARB group; median age 64 [interquartile range, 55-68] years; 53.2% men) and 940 without using ACEI/ARB (non-ACEI/ARB group; median age 64 [interquartile range 57-69]; 53.5% men), who were admitted to 9 hospitals in Hubei Province, China from December 31, 2019 to February 20, 2020. In mixed-effect Cox model treating site as a random effect, after adjusting for age, gender, comorbidities, and in-hospital medications, the detected risk for all-cause mortality was lower in the ACEI/ARB group versus the non-ACEI/ARB group (adjusted hazard ratio, 0.42 [95% CI, 0.19-0.92];P=0.03). In a propensity score-matched analysis followed by adjusting imbalanced variables in mixed-effect Cox model, the results consistently demonstrated lower risk of COVID-19 mortality in patients who received ACEI/ARB versus those who did not receive ACEI/ARB (adjusted hazard ratio, 0.37 [95% CI, 0.15-0.89];P=0.03). Further subgroup propensity score-matched analysis indicated that, compared with use of other antihypertensive drugs, ACEI/ARB was also associated with decreased mortality (adjusted hazard ratio, 0.30 [95% CI, 0.12-0.70];P=0.01) in patients with COVID-19 and coexisting hypertension. Conclusions: Among hospitalized patients with COVID-19 and coexisting hypertension, inpatient use of ACEI/ARB was associated with lower risk of all-cause mortality compared with ACEI/ARB nonusers. While study interpretation needs to consider the potential for residual confounders, it is unlikely that in-hospital use of ACEI/ARB was associated with an increased mortality risk.